Alexion's primary drug, Soliris, is one of the most expensive drugs available, costing $500,000 a year. The company is now seeking to expand Soliris to treat rare kidney diseases, which could add another $900 million to Soliris already $2 billion in revenues. Tack on other possible uses for Soliris and Cramer said Alexion could have $5.4 billion in revenue over the next few years. That's part of the reason why shares of Alexion are up 321% since Cramer first recommended it in October 2010.
Then there's Gilead Sciences, primarily known for its quad pill HIV treatment that can be taken just once a day. Gilead also has a strong hepatitis-c franchise, which could be worth $8 billion over the next six years. Cramer explained that unlike the current treatment, which is a 24-week injection regiment with varied results, Gilead's treatment is only a 12-week oral treatment that has seen 100% cure rates in some patients.
Unlike many other stocks, Alexion and Gilead are secular growers, said Cramer, and therefore don't need a strong global economy to do well.
Cramer Goes 'Bad'In a special interview, Cramer spoke with actor, writer and director Bryan Cranston, star of the new motion picture "Argo" as well as AMC's TV series "Breaking Bad." Cramer said "Breaking Bad," while centered around a highly successful drug dealer, also affords viewers an honest look into exactly what it takes to start and operate a small business. Cranston agreed with Cramer's sentiments, saying that while many view actors as portraying fantasy, in reality actors try and define the truth and honesty around their characters. In the case of "Breaking Bad," Cranston said he shadowed university professors for a few days just to better understand the world of science and chemistry. For the movie "Argo" he spent a week at CIA headquarters learning that while the spy trade does have its secretive mystique, it's also filled with the same bureaucracy we all face every day.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV